Telomir Pharmaceuticals has announced new preclinical data demonstrating that its investigational therapy, Telomir-1, reactivates two critical tumor suppressor genes—MASPIN and RASSF1A—in aggressive prostate cancer models. These genes are often silenced through DNA hypermethylation, a common mechanism in cancer progression.
In the studies, Telomir-1 reversed the hypermethylation of MASPIN, restoring its function as a natural defense protein that blocks tumor invasion and enhances treatment sensitivity. Similarly, the therapy reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy. These findings suggest that Telomir-1 may counteract chemotherapy-induced resistance and help limit metastasis.
The company claims that these results provide a compelling preclinical rationale for Telomir-1 as a first-in-class epigenetic reset therapy in oncology. Metastasis is responsible for the vast majority of cancer deaths, and chemotherapy resistance remains a major barrier to durable responses. By resetting DNA methylation and restoring tumor suppressor activity, Telomir-1 may address these persistent challenges in cancer treatment.
Telomir Pharmaceuticals is advancing Telomir-1 through IND-enabling studies, with the aim of translating these preclinical findings into clinical applications.
